Forum

The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis

Quarraisha Abdool Karim, Salim S Abdool Karim, Cheryl Baxter, Gerald Friedland, Tanuja Gengiah, Andrew Gray, Anneke Grobler, Kogileum Naidoo, Nesri Padayatchi, Wafaa El-Sadr

Authors' affiliations

Quarraisha Abdool Karim, 1) CAPRISA, Durban, 2) Department of Public Health and Family Medicine, University of KwaZulu-Natal, Durban, 3) Department of Epidemiology, Mailman School of Public Health at Columbia University

Salim S Abdool Karim, 1) CAPRISA, Durban, 2) Department of Public Health and Family Medicine, University of KwaZulu-Natal, Durban, 3) Department of Epidemiology, Mailman School of Public Health at Columbia University

Cheryl Baxter, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Gerald Friedland, Yale University School of Medicine, New Haven

Tanuja Gengiah, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Andrew Gray, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Anneke Grobler, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Kogileum Naidoo, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Nesri Padayatchi, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban

Wafaa El-Sadr, 1) Department of Epidemiology, Mailman School of Public Health at Columbia University, New York, Department of Internal Medicine and Epidemiology, Yale University School of Medicine, New Haven, 2) International Center for AIDS Care and Treatment Programs

Full Text

PDF (71KB)

Keywords

tuberculosis, HIV, treatment, antiretroviral

Cite this article

South African Medical Journal 2010;100(12):808-809.

Article History

Date submitted: 2010-10-29
Date published: 2010-12-01

Article Views

Abstract views: 1858
Full text views: 1227

Comments on this article

*Read our policy for posting comments here